osimertinib brands

2 registered brands containing osimertinib in South Africa.

Osimertinib

PubChem CID 71496458

Molecular formula: C28H33N7O2

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) that predominate in non-small cell lung cancer (NSCLC) tumours following treatment with first-line EGFR-TKIs. As a third-generation tyrosine kinase inhibitor, osimertinib is specific for the gate-keeper T790M mutation which increases ATP binding activity to EGFR and results in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity. Compared to wild-type EGFR, osimertinib has 200 times higher affinity for EGFR molecules with the L858R/T790M mutation _in vitro_.

DiseaseReactome Diseases of signal transduction by growth factor receptors and second messengersReactome Signaling by ERBB2 in CancerReactome Drug resistance in ERBB2 KD mutantsReactome Resistance of ERBB2 KD mutants to osimertinibReactome

Source: PubChem (NCBI) ยท compound 71496458

All countries Kenya Tanzania Rwanda Zambia Uganda Malawi South Africa Zimbabwe Nigeria Ghana Botswana
Product Manufacturer Status Country
TAGRISSO 40 mg - Registered South Africa
TAGRISSO 80 mg - Registered South Africa